Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer

doi:10.12998/wjcc.v10.i27.9703

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 27

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3020)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

131

WORD

HTML

1493

Figures (1-4)

352

Tables (1-2)

263

Sum=2269

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

260

Download

491

Sum=751

Sep 26, 2022 (publication date) through Dec 25, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Clin Cases. Sep 26, 2022; 10(27): 9703-9713
Published online Sep 26, 2022. doi: 10.12998/wjcc.v10.i27.9703

Table 2 Grade 3/4 toxicity with gemcitabine plus nab-paclitaxel + a targeted drug and gemcitabine plus nab-paclitaxel + placebo in metastatic pancreatic cancer

Grade 3/4 toxicity	GA+ a targeted drug (n/N)	GA+ placebo (n/N)	Analysis model	OR (95%CI)	Z	P
Fatigue	367/777	264/607	Fixed effect	1.07 (0.88,1.29)	0.642	0.522
Anemia	166/452	169/451	Fixed effect	0.97 (0.75,1.25)	0.225	0.822
Vomiting	221/663	160/497	Fixed effect	1.07 (0.84,1.36)	0.532	0.595
Neutropenia	150/452	158/451	Fixed effect	0.94 (0.73,1.22)	0.444	0.657
Diarrhea	281/452	194/451	Fixed effect	1.46 (1.17,1.83)	3.309	< 0.01

GA: Gemcitabine plus nab-paclitaxel.

Citation: Li ZH, Ma YJ, Jia ZH, Weng YY, Zhang P, Zhu SJ, Wang F. Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer. World J Clin Cases 2022; 10(27): 9703-9713
URL: https://www.wjgnet.com/2307-8960/full/v10/i27/9703.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i27.9703